Delivery of GalNAc-Conjugated Splice-Switching ASOs to Non-hepatic Cells through Ectopic Expression of Asialoglycoprotein Receptor
Splice-switching antisense oligonucleotides (ASOs) are promising therapeutic tools to target various genetic diseases, including cancer. However, in vivo delivery of ASOs to orthotopic tumors in cancer mouse models or to certain target tissues remains challenging. A viable solution already in use is...
Saved in:
Main Authors: | Juergen Scharner (Author), Sabrina Qi (Author), Frank Rigo (Author), C. Frank Bennett (Author), Adrian R. Krainer (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2'-MOE-ASOs
by: Colby S. Shemesh, et al.
Published: (2017) -
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice
by: Rosie Z Yu, et al.
Published: (2016) -
GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells
by: Sabine Sewing, et al.
Published: (2019) -
Lectin Histochemical Study of GalNac and GlcNac Containing Glycoconjugates in Colon Adenocarcinoma
by: Mohamad Reza Arab, et al.
Published: (2013) -
Evidence of gene conversion in genes encoding the Gal/GalNac lectin complex of Entamoeba.
by: Gareth D Weedall, et al.
Published: (2011)